Ebrahim Sabbagh, DO
Interventional Cardiology · Weston, WVNPI 1811332737
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (54.9%), travel and lodging and grants — rather than concentrated in one kind of arrangement. Boston Scientific accounts for 61.4% of it on its own, with 22 other manufacturers making up the rest. Reporting peaked in 2023 at $3,546 and has fallen 77.9% since, to $783 in 2025.
Across 220 payments — averaging $50.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boston Scientific$7K
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$730
- Abbott$688
- Medtronic$559
- Johnson & Johnson$426
- AstraZeneca$407
- plus $2K from 17 others
What the payments were for
- Grants$1,10510%
- Travel & lodging$3,89935%
- Food & beverage$6,13255%
- Education$420%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boston Scientific | 40 | $6,860 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 49 | $730 |
| Abbott | 13 | $688 |
| Medtronic(2 entities) | 6 | $559 |
| Johnson & Johnson | 23 | $426 |
| AstraZeneca | 23 | $407 |
| Novartis | 17 | $296 |
| Abiomed | 3 | $175 |
| Kestra Medical Technology Services, Inc. | 5 | $164 |
| Heartflow, Inc. | 5 | $153 |
| E.r. Squibb & Sons, L.L.C. | 6 | $109 |
| Cardinal Health 200 LLC | 2 | $92 |
| CSL Behring | 3 | $77 |
| Stryker | 3 | $77 |
| Boehringer Ingelheim | 5 | $73 |
| Pfizer | 4 | $61 |
| Cardiovascular Systems Inc. | 4 | $52 |
| Shockwave Medical, Inc | 2 | $44 |
| Amgen | 2 | $43 |
| Merck | 2 | $34 |
| Cardiva Medical, Inc. | 1 | $31 |
| Novo Nordisk | 1 | $16 |
| Cook Incorporated | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- AngioJet Ultra 5000A$2,386
- CROSSBOSS$1,482
- GENERAL - STRUCTURAL HEART$1,105
- EKOSONIC$513
- ANGIOJET$442
- Resolute$324
- ASSURITY$223
- GENERAL VASCULAR ACCESS$130
- GENERAL ANGIOPLASTY$114
- Confirm Rx$113
- XIENCE SIERRA$113
- Impella$109
- XARELTO$102
How this compares
$11,177 in reported general payments places this provider in the 65th percentile of 46 interventional cardiology providers in West Virginia.
See all interventional cardiology providers in West Virginia →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 86 | $94,003 |
| EntrestoSacubitril/Valsartan | 36 | $36,350 |
| XareltoRivaroxaban | 28 | $27,511 |
| BrilintaTicagrelor | 13 | $12,573 |
| FarxigaDapagliflozin Propanediol | 12 | $9,705 |
| Metoprolol Succinate | 102 | $1,662 |
| Metoprolol Tartrate | 261 | $1,543 |
| Isosorbide Mononitrate ErIsosorbide Mononitrate | 98 | $1,407 |
| Ranolazine ErRanolazine | 12 | $1,043 |
| ClopidogrelClopidogrel Bisulfate | 74 | $955 |
| Carvedilol | 85 | $932 |
| Atorvastatin Calcium | 93 | $737 |
| Furosemide | 125 | $646 |
| Amlodipine Besylate | 82 | $553 |
| Lisinopril | 74 | $547 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $61 | $94,00386 claims |
| NovartisEntresto | $296 | $36,35036 claims |
| Johnson & JohnsonXarelto | $426 | $27,51128 claims |
| AstraZenecaBrilinta, Farxiga | $407 | $22,27825 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 46 interventional cardiology providers in West Virginia.
Other interventional cardiology in Weston
- Mark BatesCharleston$288K
- Elie GharibSouth Charleston$240K
- Wissam GharibMorgantown$179K
- Anene UkaigweCharleston$168K
- Aravinda NanjundappaBeckley$166K
- Daniel SnavelyHuntington$120K
- Elise AndersonCharleston$38K
- Richard HanCharleston$38K
- Mehrette MaruHuntington$16K
- Kishore ChallaSo Charleston$14K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.